Larazotide

Larazotide acetate, also known by its development code AT-1001 and later INN-202, is a synthetic eight-amino-acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) structurally derived from the zonula occludens toxin (Zot), a toxin produced by Vibrio cholerae that opens intestinal tight junctions as part of the bacterium's diarrheal disease mechanism. Researchers recognized that the same tight-junction-opening pathway exploited by Zot is mirrored by zonulin, a human protein identified in 2000 and found to be released in excess in the intestinal tissue of people with celiac disease during gluten exposure, disassembling the tight junctions between intestinal epithelial cells and allowing gluten-derived peptides to cross into the underlying immune tissue where they trigger the celiac inflammatory cascade. Larazotide was designed as a competitive antagonist of this zonulin-driven pathway, intended to keep the intestinal barrier closed even in the presence of gluten. Development began under Alba Therapeutics, was later licensed to Innovate Biopharmaceuticals, and continued under 9 Meters Biopharma following a corporate merger; across this roughly 15-year development history, larazotide became the first celiac disease drug candidate to reach a phase 3 clinical trial, a milestone no other celiac therapeutic had achieved. Despite that milestone and a substantial phase 2 human evidence base, larazotide remains unapproved: its pivotal phase 3 trial was discontinued in 2022, and it is not available as an approved medication, a dietary supplement, or (unlike several other peptides in this queue) a commonly marketed gray-market research chemical, reflecting its development as a conventional pharmaceutical asset rather than a compounding or bodybuilding-community product.

The central mechanism of larazotide is competitive antagonism of zonulin receptor signaling at the apical surface of intestinal epithelial cells. In celiac disease, exposure to gliadin (a component of gluten) triggers release of zonulin, which activates a signaling cascade involving protease-activated receptor 2 (PAR2) and transactivation of the epidermal growth factor receptor (EGFR), ultimately causing disassembly and redistribution of tight junction proteins including claudins, occludin, and zonula occludens-1 (ZO-1), together with rearrangement of the underlying actin cytoskeleton. This disassembly opens paracellular gaps between epithelial cells wide enough for gluten-derived peptides to cross into the lamina propria, where they encounter antigen-presenting cells and drive the adaptive immune response, including antibody production against tissue transglutaminase, that defines celiac disease. By blocking zonulin receptor engagement, larazotide is designed to interrupt this cascade before the paracellular gap opens, keeping gluten-derived peptides largely confined to the intestinal lumen. Preclinical work in a porcine model of ischemic jejunal injury has directly demonstrated this tight-junction-preserving effect, showing that larazotide enhances transepithelial electrical resistance and improves localization of the sealing protein claudin-4 in repairing epithelium, and mechanistic reviews have additionally implicated modulation of myosin light chain kinase (MLCK)-dependent tight junction regulation, a pathway relevant to gut barrier function well beyond celiac disease specifically.

The larazotide human evidence base is unusually substantial for a peptide in this queue, spanning more than 800 dosed patients across several randomized controlled trials over roughly a decade and a half. Early trials established basic safety, tolerability, and pharmacodynamic proof of concept, followed by controlled experimental gluten-challenge studies in which larazotide (tested at doses from 1 to 8 milligrams three times daily) reduced gluten-induced gastrointestinal symptoms and intestinal permeability markers relative to placebo. The largest and most clinically relevant completed trial enrolled 342 celiac disease patients with persistent symptoms despite an established gluten-free diet and found that the 0.5 milligram three-times-daily dose, but not the higher 1 or 2 milligram doses, significantly improved a validated gastrointestinal symptom score over 12 weeks, with exploratory endpoints showing roughly a 26 percent reduction in symptomatic days. A subsequent meta-analysis of four randomized trials concluded that larazotide was superior to placebo for symptom relief with a safety profile comparable to placebo. Despite this consistent phase 2 signal, the pivotal 525-patient phase 3 trial, the definitive study designed to confirm the effect at scale, was discontinued in 2022 after an interim analysis found the treatment effect too small to demonstrate statistical significance within a practical sample size. This is the central honest tension in the larazotide evidence base: a real and repeatedly observed phase 2 signal that did not survive confirmation in the one trial built to be definitive.

Pharmacokinetically and from a safety standpoint, larazotide has behaved as intended: because it acts locally within the intestinal lumen and mucosa with minimal to no systemic absorption, its adverse-event profile across the full clinical trial program has been comparable to placebo, without a distinct safety signal driving the phase 3 discontinuation. This favorable tolerability is a genuine strength relative to systemically absorbed drugs and to several other peptides in this queue, but it does not substitute for confirmed efficacy; the phase 3 trial was stopped for futility, not for harm. As of the most recent public disclosures, no completed phase 3 trial for larazotide has succeeded, no regulatory approval has been granted anywhere, and the sponsor has stated an intent to further analyze existing trial data (including possible subgroup or symptom-specific benefits) and to discuss a path forward with regulators, but no confirmed renewed development program has been announced. Because larazotide was developed as a conventional pharmaceutical candidate under formal clinical trial sponsorship rather than as a compounding-pharmacy or research-chemical product, it has not been widely available through the gray-market peptide vendors that sell several other peptides in this queue, meaning there is currently no legitimate route by which a patient can obtain larazotide outside of a clinical trial.

Mechanism of Action

Zonulin Receptor Antagonism and the Gliadin-Triggered Cascade

In people with celiac disease, exposure to gliadin, a component of gluten, triggers release of zonulin, a human protein identified in 2000 that regulates the tight junctions sealing adjacent intestinal epithelial cells together. Zonulin release activates protease-activated receptor 2 (PAR2) on the epithelial cell surface, which transactivates the epidermal growth factor receptor (EGFR) and initiates a signaling cascade that disassembles tight junction proteins, including claudins, occludin, and zonula occludens-1 (ZO-1), while simultaneously triggering rearrangement of the underlying actin cytoskeleton. The net effect is a widening of the paracellular space between epithelial cells, large enough for gluten-derived peptides to cross from the intestinal lumen into the lamina propria, where they encounter antigen-presenting cells and drive the adaptive immune response, including generation of antibodies against tissue transglutaminase, that defines celiac disease pathology. Larazotide is a synthetic octapeptide structurally derived from the zonula occludens toxin (Zot) produced by Vibrio cholerae, the bacterial toxin whose tight-junction-opening activity first led researchers to discover the human zonulin pathway, and it is designed to competitively interfere with zonulin receptor engagement, blocking this cascade before the paracellular gap opens.

Tight Junction Protein Preservation

Downstream of blocking zonulin receptor signaling, larazotide has been shown directly to preserve tight junction protein architecture. In a porcine model of ischemia-induced jejunal injury, larazotide treatment enhanced recovery of transepithelial electrical resistance, a standard physiological measure of epithelial barrier integrity, and improved localization of claudin-4, one of the key sealing proteins in the tight junction complex, in the repairing intestinal epithelium. This finding demonstrates that the tight-junction-protective effect of larazotide is not limited to blocking gliadin-triggered zonulin release specifically, but extends to a distinct model of physical intestinal barrier injury, suggesting a more general tight-junction-stabilizing action.

Myosin Light Chain Kinase and Broader Barrier Regulation

Mechanistic reviews of larazotide have additionally implicated modulation of myosin light chain kinase (MLCK)-dependent tight junction regulation, a signaling node that controls the contractile perijunctional actomyosin ring responsible for physically pulling tight junction proteins apart during barrier disruption. MLCK activation is a shared downstream mechanism across multiple causes of intestinal barrier breakdown, including inflammatory cytokine exposure and ischemic injury, which may help explain why larazotide has shown tight-junction-protective effects in models (porcine ischemia, rodent acute liver failure) that have nothing to do with gluten or celiac disease specifically.

Local, Non-Systemic Pharmacology

A defining feature of larazotide pharmacology is that it acts almost entirely within the intestinal lumen and mucosa rather than being absorbed into systemic circulation. Across the clinical trial program, plasma concentrations of intact larazotide have generally been undetectable or below the limit of quantification in the large majority of subjects even at higher milligram-range doses, a pharmacokinetic profile that is a deliberate design goal rather than an incidental finding, since the zonulin receptor target is located at the apical, lumen-facing surface of intestinal epithelial cells. This local mechanism is the proposed explanation for the consistently placebo-comparable adverse-event profile observed across the larazotide trial program.

Clinical Evidence

Early Proof of Concept and Gluten-Challenge Trials

The first human trial of larazotide, published in 2007, established the safety, tolerability, and basic pharmacodynamic effect of single oral doses up to 12 milligrams in celiac disease subjects and confirmed minimal systemic absorption. Subsequent randomized, double-blind, placebo-controlled trials used a controlled experimental gluten challenge, typically 2.7 grams of gluten daily for several weeks, in celiac disease patients otherwise maintaining a gluten-free diet, to test whether larazotide could blunt the gluten-triggered symptomatic and biomarker response. A 184-patient dose-ranging trial testing 1, 4, and 8 milligrams three times daily found that larazotide reduced gluten-induced gastrointestinal symptoms and intestinal permeability biomarkers relative to placebo and was generally well tolerated, establishing the initial efficacy signal for the drug candidate in a controlled human model of celiac disease activation.

The Persistent Symptoms Trial and Its Non-Monotonic Dose-Response

The largest and most clinically relevant completed trial, published in 2015, enrolled 342 celiac disease patients with persistent gastrointestinal symptoms despite following a gluten-free diet for at least 12 months, a population representing ongoing unmet need since a meaningful proportion of treated celiac patients continue to experience symptoms from inadvertent gluten exposure or incomplete mucosal healing. Patients were randomized to placebo or to larazotide 0.5, 1, or 2 milligrams three times daily for 12 weeks. Only the 0.5 milligram dose met the prespecified primary endpoint, significantly improving the Celiac Disease Gastrointestinal Symptom Rating Scale score compared with placebo, with exploratory analyses showing roughly a 26 percent reduction in symptomatic days and a 31 percent increase in improved-symptom days. The 1 and 2 milligram doses, counterintuitively, performed no better than placebo. This non-monotonic dose-response, in which a middle or lower dose outperforms higher doses, is not fully mechanistically explained and has been a persistent complication for larazotide dose selection in later development.

Meta-Analytic Synthesis of the Phase 2 Evidence

A 2021 systematic review and meta-analysis pooling four randomized controlled trials (n=626 total, 465 patients receiving larazotide and 161 receiving placebo) concluded that larazotide was statistically superior to placebo for gastrointestinal symptom relief, whether in the context of an experimental gluten challenge or persistent real-world symptoms, with an overall safety profile comparable to placebo. This meta-analysis represented the most favorable, consolidated statement of the larazotide evidence base and was published shortly before the pivotal phase 3 trial results became known.

Phase 3 Discontinuation

Larazotide became the first celiac disease drug candidate to reach a phase 3 clinical trial, a 525-patient study conducted at more than 100 sites across the United States and Canada testing 0.25 and 0.5 milligram three-times-daily doses against placebo over 24 weeks. In 2022, the trial was discontinued after an interim analysis found that the treatment effect size was too small to reliably demonstrate statistical significance within a practical, achievable sample size; the discontinuation was for futility rather than for a safety concern. The sponsor has indicated an intent to further analyze the accumulated trial data, including possible symptom-specific or subgroup benefits, and to discuss next steps with regulators, but no confirmed renewed development program has followed as of the most recent public disclosures. This outcome is the central honest caveat for larazotide: a real, reproducible phase 2 signal across multiple independent trials did not survive confirmation in the one trial specifically designed and statistically powered to be definitive.

Safety and Tolerability

Across a clinical trial program that has dosed more than 800 patients, larazotide has consistently produced an adverse-event profile comparable to placebo, with headache and mild gastrointestinal symptoms such as constipation reported at similar rates in both treatment and placebo arms. No serious drug-related adverse events or dose-limiting toxicities have been identified in any completed trial, and the phase 3 discontinuation was explicitly attributed to insufficient efficacy separation from placebo rather than to any safety signal. Long-term safety beyond 24 weeks of continuous dosing, the longest duration studied, has not been established.

Regulatory Status

Larazotide acetate is not approved as a drug in the United States, the European Union, or any other jurisdiction, and no regulatory filing for approval has been completed given the discontinuation of its pivotal phase 3 trial for futility. It remains an investigational compound with a substantial phase 2 human trial history but no confirmed pivotal result. Unlike several other peptides covered in this series, larazotide has not been widely available through unregulated research-chemical or gray-market peptide vendors, a difference attributable to its development as a conventional, patent-protected pharmaceutical candidate under a formal clinical trial sponsor (successively Alba Therapeutics, Innovate Biopharmaceuticals, and 9 Meters Biopharma) rather than as a compounding-pharmacy or bodybuilding-community product. There is currently no legitimate, quality-controlled route by which a patient can obtain larazotide outside of an active clinical trial, and no such trial is known to be actively enrolling as of the most recent public disclosures.

Dosing Guidance

No dose of larazotide has been established as an approved or clinically validated therapeutic regimen. The doses studied across the clinical trial program ranged from single doses up to 12 milligrams in the earliest safety study, to 1, 4, and 8 milligrams three times daily during gluten-challenge trials, to 0.5, 1, and 2 milligrams three times daily in the largest persistent-symptoms trial, where only the 0.5 milligram dose met its primary endpoint, to 0.25 and 0.5 milligrams three times daily in the discontinued phase 3 program. Every trial dosed larazotide three times daily, generally around meals, and studied it strictly as an adjunct to an existing gluten-free diet rather than as a substitute for dietary gluten avoidance. Because no confirmatory trial has succeeded and no regulatory approval exists, none of these doses should be read as a recommended protocol.